title: Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.
abstract: BACKGROUND
  Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or delivery systems, we aimed to encapsulate recombinant SAG1 (rSAG1) with the PLG polymers to prepare PLG-encapsulated rSAG1 (PLG-rSAG1) microparticles that would sustain rSAG1 release and generate long-lasting protective immunity against T. gondii in BALB/c mice.
  
  
  METHODS
  In the present study, rSAG1 was encapsulated into PLG microparticles by the double emulsion method. PLG-rSAG1 microparticles were then intraperitoneally injected twice at a 14-day interval into BALB/c mice. We examined the ability of PLG-rSAG1 microparticles to induce and prolong effective anti-Toxoplasma immune responses, in comparison with rSAG1 formulated with a Vet L-10 adjuvant (rSAG1 (Vet L-10)). Eight weeks after the last immunization, protective activities were also evaluated after a lethal subcutaneous challenge of 1 x 10(4) live T. gondii tachyzoites.
  
  
  RESULTS
  PLG-rSAG1 microparticles, 4.25~6.58 micrometers in diameter, showed 69%~81% entrapment efficiency. The amount of released rSAG1 protein from microparticles increased gradually over a 35-day period and the protein still retained native SAG1 antigenicity. Intraperitoneal vaccination of mice with the microparticles resulted in enhanced SAG1-specific IgG titers as well as lymphocyte proliferation and, more importantly, these enhanced activities were maintained for 10 weeks. In addition, eight weeks after the last immunization, maximum production of gamma interferon was detected in mice immunized with PLG-rSAG1 microparticles. Furthermore, 80% (8/10) of mice immunized with PLG-rSAG1 microparticles survived at least 28 days after a lethal subcutaneous tachyzoite challenge.
  
  
  CONCLUSIONS
  Encapsulation of rSAG1 into PLG microparticles preserves the native SAG1 antigenicity and sustains the release of rSAG1 from microparticles. PLG-rSAG1 microparticles can effectively induce not only significant long-lasting SAG1-specific humoral and cell-mediated immune responses but also high protection against T. gondii tachyzoite infection. Our study provides a valuable basis for developing long-lasting vaccines against T. gondii for future use in humans and animals.
authors: Department of Physiology, College of Medicine, Kaohsiung Medical University, No 100, Shih-Chuan 1st Road, Kaohsiung 807, Taiwan.
authors: Shu-Chun
authors: SC
authors: Chuang
authors: Jing-Chun
authors: JC
authors: Ko
authors: Chaio-Ping
authors: CP
authors: Chen
authors: Jia-Tze
authors: JT
authors: Du
authors: Chung-Da
authors: CD
authors: Yang
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage*; D005260:Female; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D011098:Polyglactin 910 / Q000008:administration & dosage*; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology*; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D016019:Survival Analysis; D014122:Toxoplasma / Q000235:genetics / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000276:immunology / Q000517:prevention & control; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D004337:Drug Carriers; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; C047168:SAG1 antigen, Toxoplasma; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D011098:Polyglactin 910; D007371:Interferon-gamma
references: Arch Virol. 2011 Feb;156(2):183-202
references: 21170730
references: Microbes Infect. 2003 Apr;5(5):457-62
references: 12738002
references: Mem Inst Oswaldo Cruz. 2009 Mar;104(2):246-51
references: 19430650
references: Infect Immun. 2002 Jan;70(1):185-91
references: 11748181
references: J Control Release. 2005 Dec 5;109(1-3):62-76
references: 16269200
references: J Control Release. 2003 Jul 31;90(3):261-80
references: 12880694
references: PLoS One. 2012;7(4):e35834
references: 22558235
references: Infect Immun. 2002 Feb;70(2):434-43
references: 11796568
references: Vaccine. 2010 Mar 16;28(13):2556-64
references: 20117266
references: Pharm Res. 1993 Mar;10(3):362-8
references: 8464808
references: Curr Opin Immunol. 1993 Aug;5(4):532-7
references: 8216929
references: Expert Rev Vaccines. 2011 Dec;10(12):1731-42
references: 22085176
references: Vaccine. 1999 Mar 5;17(9-10):1047-56
references: 10195614
references: Vaccine. 2004 Sep 28;22(29-30):3929-41
references: 15364441
references: J Biomed Mater Res. 2002 Jun 5;60(3):480-6
references: 11920673
references: Infect Genet Evol. 2012 Mar;12(2):359-68
references: 22226702
references: Pharm Res. 1997 Nov;14(11):1556-62
references: 9434274
references: Parasit Vectors. 2012 Nov 26;5:273
references: 23181694
references: J Eukaryot Microbiol. 2008 Nov-Dec;55(6):467-75
references: 19120791
references: Parasitol Res. 2004 Jan;92(1):58-64
references: 14605877
references: Clin Microbiol Infect. 2002 Oct;8(10):634-40
references: 12390281
references: Parasit Vectors. 2011 Nov 09;4:213
references: 22070984
references: Parasitol Res. 2003 Dec;91(6):452-7
references: 14564510
references: J Mater Sci Mater Med. 2009 Aug;20(8):1669-75
references: 19283453
references: Science. 1988 Apr 22;240(4851):516-8
references: 3128869
references: J Immunol. 2000 Mar 1;164(5):2629-34
references: 10679102
references: Mem Inst Oswaldo Cruz. 2009 Mar;104(2):252-66
references: 19430651
references: Int J Parasitol. 1996 Feb;26(2):169-73
references: 8690540
references: Parassitologia. 2008 Jun;50(1-2):45-50
references: 18693556
references: Int J Parasitol. 2003 May;33(5-6):469-78
references: 12782048
references: Vaccine. 2006 Feb 27;24(9):1359-66
references: 16233937
references: BMC Biotechnol. 2007 Sep 27;7:62
references: 17900346
references: Am J Med. 2005 Mar;118(3):212-6
references: 15745715
references: Parasitol Today. 1993 Sep;9(9):335-7
references: 15463799